Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity

Metformin is the mainstay therapy for type 2 diabetes (T2D) and many patients also take salicylate-based drugs [i.e., aspirin (ASA)] for cardioprotection. Metformin and salicylate both increase AMP-activated protein kinase (AMPK) activity but by distinct mechanisms, with metformin altering cellular...

Full description

Saved in:
Bibliographic Details
Published in:Biochem J
Main Authors: Ford, Rebecca J., Fullerton, Morgan D., Pinkosky, Stephen L., Day, Emily A., Scott, John W., Oakhill, Jonathan S., Bujak, Adam L., Smith, Brennan K., Crane, Justin D., Blumer, Regje M., Marcinko, Katarina, Kemp, Bruce E., Gerstein, Hertzel C., Steinberg, Gregory R.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5233440/
https://ncbi.nlm.nih.gov/pubmed/25742316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BJ20150125
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items